Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment;Miejsce leukotrienów w patofizjologii astmy oskrzelowej. konieczność leczenia przeciwleukotrienowego

Pneumonologia i Alergologia Polska

Volumn 78, Issue 1, 2010, Pages 68-73

  Fal, Andrzej M ^a,b   Kopeć, Agnieszka ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Katedra i Klinika Chorob Wewnetrznych   (Poland)

Author keywords

Allergic rhinitis; Antileukotrienes; Asthma; Cysteinyl leukotrienes; Inflammation; Leukotrienes

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADULT; ASTHMA; BRONCHUS HYPERREACTIVITY; CHILD; DOSE RESPONSE; DRUG COMBINATION; HAY FEVER; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW;

ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; PRACTICE GUIDELINES AS TOPIC; RHINITIS, ALLERGIC, SEASONAL;

EID: 77950508732     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Mondino C., Ciabattoni G., Koch P., i wsp. Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. J. Allergy Clin. Immunol. 2004; 114: 761-767.
2. Yopp A.C., Randolph G.J., Bromberg J.S. Leukotrienes, sphingolipids, and leukocyte trafficking. J. Immunol. 2003; 171: 5-10.
3. Figueroa D.J., Breyer R.M., Defoe S.K., i wsp. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes Am. J. Respir. Crit. Care Med. 2001; 163: 226-233.
4. Shirasaki H., Kanaizumi E., Watanabe K., i wsp. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin. Exp. Allergy 2002; 32: 1007-1012.
5. Okunishi K., Dohi M., Nakagome K., i wsp. A novel role of cysteinyl leukotrienes to promote dendritic cell activation in the antigen-induced immune responses in the lung. J. Immunol. 2004; 173: 6393-6402.
6. Heise C.E., O'Dowd B.F., Figueroa D.J. i wsp. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 2000; 275: 30 531-30 536.
7. Hui Y., Cheng Y., Smalera I., i wsp. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 2004; 110: 3360-3366.
8. Montuschi P., Sala A., Dahlen S.E., Folco G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov. Today 2007; 12: 404-412.
9. Parameswaran K., Liang H., Fanat A., i wsp.: Role for cysteinyl leukotrienes in allergen-induced change in circulating dendritic cell number in asthma. J. Allergy Clin. Immunol. 2004; 114: 73-79.
10. Robbiani D.F., Finch R.A., Jäger D., i wsp. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000; 103: 757-768.
11. Chibana K., Ishii Y., Asakura T., Fukuda T. Effect of cysteinyl leukotriene on the antigen presenting function of monocytesderived dendritic cells. Am. J. Respir Crit. Care Med. 2004; 169: 62.
12. Lamoureux J., Stankova J., Rola-Pleszczynski M. Leukotriene D4 enhances immunoglobulin production in CD40-activated human B lymphocytes. J. Allergy Clin. Immunol. 2006; 117: 924-930.
13. Kim D.C., Hsu F.I., Barrett N.A., i wsp. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J. Immunol. 2006; 176: 4440-4448.
14. Miadonna A., Tedeschi A., Leggieri E., i wsp. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am. Rev. Respir. Dis. 1987; 136: 357-362.
15. Haberal I., Corey J.P. The role of leukotrienes in nasal allergy. Otolaryngol. Head Neck Surg. 2003; 129: 274-279.
16. Henderson W.R. Jr. The role of leukotrienes in inflammation. Ann. Intern. Med. 1994; 121: 684-697.
17. Bisgaard H., Olsson P., Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin. Allergy 1986; 16: 289-297.
18. Okuda M., Watase T., Mezawa A., Liu C.M. The role of leukotriene D4 in allergic rhinitis. Ann. Allergy 1988; 60: 537-540.
19. Björck T., Dahlén S.E. Leukotrienes and histamine mediate IgEdependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Pulm. Pharmacol. 1993; 6: 87-96.
20. Bautz F., Denzlinger C., Kanz L., Mohle R. Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1. Blood 2001; 97: 3433-3440.
21. Pipkorn U., Proud D., Lichtenstein L.M., i wsp. Effect of shortterm systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J. Clin. Invest. 1987; 80: 957-961.
22. Tager A.M., Luster A.D. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot. Essent. Fatty Acids 2003; 69: 123-134.
23. Bisgaard H., Nielsen K.G. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am. J. Respir. Crit. Care Med. 2000; 162: 187-190.
24. Szczeklik A., Sanak M. Genetic mechanisms in aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 2000; 161: 142-146.
25. Sanak M., Simon H.U., Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599-1600.
26. Sampson A.P., Siddiqui S., Buchanan D., i wsp. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 (supl. 2): S28-S31.
27. Kato J., Kohyama T., Okazaki H., i wsp. Leukotriene D4 potentiates fibronectin-induced migration of human lung fibroblasts. Clin. Immunol. 2005; 117: 177-181.
28. Dicpinigaitis P.V., Dobkin J.B., Reichel J. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J. Asthma 2002; 39: 291-297.
29. Barnes N.C., Miller C.J. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax 2000; 55: 478-483.
30. Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999; 340: 197-206.
31. Sandrini A., Ferreira I.M., Gutierrez C., i wsp. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest 2003; 124: 1334-1340.
32. Montuschi P., Mondino C., Koch P., i wsp. Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma. Chest 2007; 132: 1876-1881.
33. Pizzichini E., Leff J.A., Reiss T.F., i wsp. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur. Respir. J. 1999; 14: 12-18.
34. Hui K.P., Barnes N.C. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062-1063.
35. Reiss T.F., Sorkness C.A., Stricker W., i wsp. Thorax Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52: 45-48.
36. Dahlén S.E., Malmström K., Nizankowska E., i wsp. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2002; 165: 9-14.
37. Mastalerz L., Gawlewicz-Mroczka A., Nizankowska E., i wsp. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin. Exp. Allergy 2002; 32: 1360-1365.
38. Philip G., Villarán C., Pearlman D.S., i wsp. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J. Asthma 2007; 44: 213-217.
39. Dessanges J.F., Préfaut C., Taytard A., i wsp. The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness. J. Allergy Clin. Immunol. 1999; 104: 1155-1161.
40. Henderson W.R. Jr, Tang L.O., Chu S.J., i wsp. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am. J. Respir. Crit. Care Med. 2002; 165: 108-116.
41. Muz M.H., Deveci F., Bulut Y., i wsp. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model. Exp. Mol. Med. 2006; 38: 109-118.
42. Henderson W.R. Jr, Chiang G.K., Tien Y.T., Chi E.Y. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am. J. Respir. Crit. Care Med. 2006; 173: 718-728.
43. Kelly M.M., Chakir J., Vethanayagam D., i wsp. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 2006; 130: 741-753.
44. GINA revised 2008 (www.ginasthma.org).
45. Bleecker E.R., Welch M.J., Weinstein S.F., i wsp. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J. Allergy Clin. Immunol. 2000; 105 (6 cze{ogonek}ść 1): 1123-1129.
46. Lofdahl C.G., Reiss T.F., Leff J.A., i wsp. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319: 87-90.
47. Price D.B., Hernandez D., Magyar P., i wsp. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211-216.
48. Ringdal N., Eliraz A., Pruzinec R., i wsp. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir. Med. 2003; 97: 234-241.
49. Fish J.E., Israel E., Murray J.J., i wsp. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120: 423-430.
50. Nelson H.S., Busse W.W., Kerwin E., i wsp. Fluticasone propionate/ salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J. Allergy Clin. Immunol. 2000; 106: 1088-1095.
51. Nayak A.S., Philip G., Lu S., i wsp.; Montelukast Fall Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann. Allergy Asthma Immunol. 2002; 88: 592-600.
52. Leff J.A., Busse W.W., Pearlman D., i wsp. Montelukast, a leukotriene- receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. 1998; 339: 147-152.
53. Currie G.P., Lee D.K., Srivastava P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest 2005; 128: 2954-2962.
54. Philip G., Malmstrom K., Hampel F.C., i wsp. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin. Exp. Allergy 2002; 32: 1020-1028.
55. van Adelsberg J., Philip G., Menten J., i wsp. Flexible dosing of montelukast for treatment of seasonal allergic rhinitis: morning or evening. J. Allergy Clin. Immunol. 2003; 111: S146.
56. Taramarcaz P., Gibson P.G. The effectiveness of intranasal corticosteroids in combined allergic rhinitis and asthma syndrome. Clin. Exp. Allergy 2004; 34: 1883-1889.
57. Philip G., Nayak A.S., Berger W.E., i wsp. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr. Med. Res. Opin. 2004; 20: 1549-1558.
58. Philip G., Williams-Herman D., Patel P., i wsp. Efficacy of montelukast for treating perennial allergic rhinitis. Allergy Asthma Proc. 2007; 28: 296-304.
59. Patel P., Philip G., Yang W., i wsp. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 2005; 95: 551-557.
60. Peters-Golden M., Swern A., Bird S.S., i wsp. Influence of body mass index on the response to asthma controller agents. Eur. Respir. J. 2006; 27: 495-503.
61. Spector S. Noncompliance with asthma therapy - are there solutions? J. Asthma 2000; 37: 381-388.